

CLAIMS

What is claimed is:

5

1. A method for the treatment or prophylaxis of a human infected with hepatitis B virus comprising administering in combination or alternation an effective amount of:

β-L-FTC;

10

L-FMAU; and

interferon;

or their pharmaceutically acceptable salts or prodrugs, independently optionally in pharmaceutically acceptable carriers.

15

2. The method of claim 1, wherein the β-L-FTC is in substantially pure form.

3. The method of claim 1, wherein the β-L-FTC is at least 90% by weight of the β-L-isomer.

20

4. The method of claim 1, wherein the β-L-FTC is at least 95% by weight of the β-L-isomer.

25

5. The method of claim 1, wherein the interferon is selected from the group consisting of interferon alpha, pegylated interferon alpha, interferon alpha-2a, interferon alpha-2b, pegylated interferon alpha-2a, pegylated interferon alpha-2b ROFERON®-A (interferon alpha-2a), PEGASYS® (pegylated interferon alpha-2a), INTRON®A (Interferon alpha-2b), PEG-INTRON® (pegylated Interferon alpha-2b), interferon beta, interferon gamma, interferon tau, interferon omega, consensus interferon, INFERGEN (interferon alphacon-1), OMNIFERON (natural interferon), REBIF (interferon beta-1a), omega interferon, oral interferon alpha, interferon gamma-1b, SuperFeron (natural human multi-subtype IFN-alpha), and HuFeron (human IFN-beta).

6. The method of claim 5, wherein the interferon is interferon alpha.
7. The method of claim 5, wherein the interferon is interferon gamma.
- 5 8. The method of claim 5, wherein the interferon is interferon beta.